Endocrine-Related Cancer

Article	Citations
Acknowledgement to reviewers	115
Survival following resection of 10,244 lung neuroendocrine tumours: a population study	96
Refining long-term surveillance requirements in patients with differentiated thyroid cancer	69
ERRATUM: Roles of the HOXA10 gene during castrate-resistant prostate cancer progression	52
Defining aging-associated factors that increase susceptibility to prostate cancer	49
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms	49
Acknowledgement to reviewers	48
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients	35
Prognostic of recurrence and survival in poorly differentiated thyroid cancer	35
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications	34
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing	34
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas	34
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	31
Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study	30
Update on the genetics of paragangliomas	28
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells	28
Targeting growth hormone in cancer: future perspectives	27
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells	26
Radiation reprograms fibroblasts to drive prostate cancer therapy resistance	26
Metastatic neuroendocrine neoplasms of the breast: a systematic review	26
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination and degradation	25
Peptide receptor radionuclide therapy in malignant insulinoma	25
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas	24
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts	24
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet	22

Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation	21
Impact of sex hormones on development and progression in NEN: a new therapeutic target?	21
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells	19
Metabolically active brown adipose tissue in PPGL: an observational cohort study	18
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells	18
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma	18
Whole-exome sequencing of rectal neuroendocrine tumors	17
CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours	16
Rising incidence of follicular thyroid carcinoma and oncocytic carcinoma of the thyroid in Australia	16
Gender-affirming care and endocrine-related cancers	16
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring	15
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer	15
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen	15
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly	15
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective	15
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis	14
Immunotherapy for endocrine tumours: a clinician’s perspective	14
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction	14
Steroid profile in patients with breast cancer and in mice treated with mifepristone	13
Effect of TSH levels during active surveillance of PTMC according to age	13
From bench to bedside in the sella: translational developments in pituitary tumour genetics	13
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms	13
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer	13
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study	13
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis	12
Exploring stem cell biology in pituitary tumors and derived organoids	12
Inhibition of GATA2 in prostate cancer by a clinically available small molecule	12
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors	12
Ciliogenesis in pancreatic neuroendocrine tumors: insight into the role of WDR60	12
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma	12
ThyroidPrint®: clinical utility for indeterminate thyroid cytology	12
Acknowledgement to reviewers	12
Acknowledgement to reviewers	12
Clinical features of plurihormonal pituitary adenoma subtypes	11
Systems biology successes and areas for opportunity in prostate cancer	11
ERRATUM: Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2	11
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study	11
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review	11
Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer	11
New therapeutic opportunities for women with low-grade serous ovarian cancer	11
In vivo and in vitro analysis of functional effects of the SDHD H50R variant	11
Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma	11
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland	10
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review	10
Cancer in Ecuadorian subjects with Laron syndrome (ELS)	10
Genetic disorders and insulinoma/glucagonoma	10
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid	10
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management	10
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity	10
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice	10

miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2	9
Surrogate molecular classification of LAR breast cancer in routine workflow	9
Beyond the three P’s: adrenal involvement in MEN1	9
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort	9
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer	9
In memoriam: Charis Eng MD PhD (1962–2024)	9
The science behind the relations among cancer, height, growth patterns, and growth hormone axis	9
Sexual dimorphism in thyroid cancer: evidence from preclinical studies	9
Non-pituitary GH regulation of the tissue microenvironment	9
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes	9
Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis	9
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal	9
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma	9
Deiodinases in thyroid tumorigenesis	9
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms	8
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane	8
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer	8
MicroRNAs as regulators of tumor metabolism	8
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer	8
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer	8
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover	8
Genetic variants and down-regulation of CACNA1H in pheochromocytoma	8
Genotype-specific development of MEN 2 constituent components in 683 RET carriers	8
Precocious puberty due to intracranial germ cell tumors: a case–control study	8
Management of high-grade neuroendocrine neoplasms: impact of functional imaging	8
Exploring chromosomal instability and clonal heterogeneity in breast cancer	7
Insulinomatosis: new aspects	7
Rethinking paraganglioma management: distinct clinical pathways for head and neck versus other sites	7
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma	7
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer	7
MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells	7
A clinically applicable molecular classification of oncocytic cell thyroid nodules	7
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center	7
Chemoembolization using streptozotocin versus embolization in metastatic NETs	7
Unregulated LDL cholesterol uptake is detrimental to breast cancer cells	7
DNA methylation is a comprehensive marker for pediatric adrenocortical tumors	7
Reciprocal cancer risks between thyroid and breast cancer: a systematic review and meta-analysis	7
Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma	7
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms	7
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading	7
Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic revie	7
Endocrine cancer trends 1990–2021: global disparities and health inequalities	7
GLP1 receptor agonism alters growth and therapeutic response in prostate cancer	7
Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis	6
Pathological features in non-neoplastic congenital and adult hyperinsulinism: from nesidioblastosis to current terminology and understanding	6
Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations	6
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study	6
Management of advanced high grade gastro-enteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature	6
Multimodal treatment for resectable neuroendocrine carcinoma of the cervix	6
Sig27 stratifies prostate cancer recurrence by assessing the immunosuppressive properties of tumors	6
SYT7 plays a role in promoting thyroid cancer by mediating HMGB3 ubiquitination	6
Predictors of cancer in patients with endogenous Cushing’s syndrome	6
Role of GDH and PARP inhibitors as novel treatments for SDHB-deficient PPGLs	6
Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer	6
Inflammation-based score in pediatric adrenocortical carcinoma	6
The aggressiveness of succinate dehydrogenase subunit B-deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide	5
Insulin-like growth factor-1 receptor crosstalk with integrins, cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in cancer	5
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer	5
Clinicopathologic features of thyroid nodules with PTEN mutations on preoperative testing	5
Hallmarks of Disease: How tuned hierarchies of intelligent molecular neural networks (MNNs) may matter	5
Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas	5
Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms	5
ERRATUM: Mutational landscape of non-functional adrenocortical adenomas	5
Association of DNA methylation with steroidogenic enzymes in Cushing’s adenoma	5
TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models	5
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma	5
Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome	5
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study	5
Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk?	5
The prevalence and clinical significance of Ga-68-DOTANOC incidentaloma	5
Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer	5
ERRATUM: The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2	5
Pituitary tumor-transforming gene 1 and endocrine cancers: an up-to-date review through history, current insights and future perspectives	5
Progress and challenges in experimental models for pheochromocytoma and paraganglioma	5
Netrin–DCC inhibition suppresses neuroendocrine neoplasm growth in vivo	4
NIFTPs may be reclassified not only from FVPTCs but also from follicular adenomas	4
β-Catenin activation and illicit receptor expression in adrenocortical cells	4
Phenotype of pheochromocytoma and paraganglioma by germline mutation: a Korean multicenter study	4
Mechanisms of resistance to RET-directed therapies	4
Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN	4

Why do we continue to have an incomplete understanding of estrogen receptor(s) actions in cancer systems?	4
Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms	4
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care	4
Nuclear and mitochondrial DNA alterations in pheochromocytomas and paragangliomas, and their potential treatment	4
Autocrine/paracrine growth hormone in cancer progression	4
Therapeutic inhibition of ATR in differentiated thyroid cancer	4
Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases	4
Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients	4
Development and validation of long-acting recombinant human TSH using SAFA technology	4
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study	4
Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas	4
Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma	4
The role of membrane mucin MUC4 in breast cancer metastasis	4
Core needle biopsy in pheochromocytoma/paraganglioma: should it be considered?	4
Second primary cancers and survival among neuroendocrine tumor patients	4
AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma	4
Improved and individualized approach to adrenal surgery	4
Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer	3
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients	3
Clinical relevance of the thyroid differentiation score (TDS) in benign and malignant thyroid tumors	3
Growth hormone and radiation therapy: friend, foe, or both?	3
Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis	3
Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review	3
Prognostic value of the Weiss and Wieneke (AFIP) scoring systems in pediatric ACC – a mini review	3
Clinicopathological characteristics associated with the prognosis of recurrent gonadotroph tumors	3
Functional analysis of AIP variants in a cohort of neuroendocrine neoplasms	3
An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms	3
Heme-oxygenase-1: a key player in thyroid carcinoma development	3
FT3 and FT3/FT4 ratio are decreased and not compensated by levothyroxine treatment in TKI-treated thyroid cancer patients	3
One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones	3
Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors	3
The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas	3
Pregnancy-associated breast cancer: the influence of gestational age	3
Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells	3
Mannose enhances anti-tumor effect of PLX4032 in anaplastic thyroid cancer	3
Reappraisal of BRAFK601E-positive thyroid tumors in the NIFTP era	3
Oxygen regulates proliferation and phenotype in the RS0 SDH-deficient pheochromocytoma cell line	3
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial	3
Impact of presurgical beta-blockade on surgical outcomes in patients with PPGLs	3
RETRACTION: Improvement of chemotherapeutic drug efficacy by endoplasmic reticulum stress	2
The role of vitamin D in breast cancer risk and progression	2
Talking about sex: erectile dysfunction in the oncology patient	2
The allelic regulation of tumor suppressor ADARB2 in papillary thyroid carcinoma	2
Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer	2
Predictors of survival outcomes in patients with neuroendocrine neoplasms: a real-world retrospective study	2
Identification of protein-coding genes associated with metastatic prostate cancer	2
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome	2
Targeting RET in medullary thyroid cancer	2
GIPR in GH-PitNETs: molecular and functional insights	2
Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers	2
Familial Mahvash disease with metastatic pancreatic NET and MEN1 mutations	2
Mechanisms of RET-mediated signal transduction	2
Global trends in thyroid cancer 1990–2021: an analysis based on the GBD 2021	2
Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma	2
Prognostic stratification for patients with neuroendocrine tumours receiving 177Lu-Dotatate	2
Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline	2
Changes in categorization or nomenclature within neuroendocrine tumors	2
Clinical differences and surgery in follicular vs oncocytic thyroid carcinomas	2
Aldosterone-producing nodules and CYP11B1 signaling correlate in primary aldosteronism	2
Detection and yield of thyroid cancer surveillance in adults with PTEN hamartoma tumour syndrome	2
Disease relapse in relation to lymph node sampling in lung carcinoid patients	2
Targeting METTL3 induces a metabolic vulnerability in ER+ breast carcinoma cells	2
Key factors for effective mitotane therapy in children with adrenocortical carcinoma	2
Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms	2
Real-world outcomes of lenvatinib therapy for advanced neuroendocrine neoplasms	2
Liquid biopsies in thyroid cancers: a systematic review and meta-analysis	2
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine	2
Aggressive versus indolent insulinomas: new clinicopathological insights	2
Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma	2
IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer	2
Dysregulation of splicing variants and spliceosome components in breast cancer	2
Pituitary-testis axis dysfunction following adjuvant androgen deprivation therapy	2
Genomic testing for RET in the clinic: UK and global perspective	2
A study of acromegaly-associated headache with somatostatin analgesia	2
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	2
TREM1 fosters an immunosuppressive tumor microenvironment in papillary thyroid cancer	2
A zebrafish xenotransplant model of anaplastic thyroid cancer to study tumor microenvironment and innate immune cell interactions in vivo	2